Global Antisense and RNAi Therapeutics Market - Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Upcoming Report
  • Jan 2020
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Antisense and RNAi Therapeutics Market By Indication (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases and Others), By Technology  (RNA Interference, Antisense RNA), By Route of Administration (Pulmonary Delivery, Intravenous Injections, Intra-Dermal, Intraperitoneal, Topical, Others), By End Users (Hospitals, Specialty Clinics, Others), By  Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), By Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa), Market Trends and Forecast to 2027

Market Analysis and Insights: Global Antisense and RNAi Therapeutics Market

Antisense and RNAi therapeutics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Rising prevalence of the genetic diseases, neurological disorders and advancement in the biotechnological sector are the factors responsible for the growth of this market.

Advancement in the treatment options to target specificity and selectivity accelerates the growth of antisense and RNAi therapeutics market. Rapid adoption of newer formulations and novel drug delivery drives the RNA therapeutics market growth. In addition, approval and launch of RNA therapeutics is one of the impactful reasons that plays an immense role in the growth of this market.  Furthermore, special designation from the regulatory authority for novel therapies can consider the key factors to drive the market growth.

Antisense and RNAi therapeutics the new class of drugs that exert their effect either by silencing a portion of RNA through the use of short interfering RNAs (siRNAs) or microRNAs (miRNAs) which is involved in causing the disease or induces the degradation of targeted mRNA by RNase and thus reducing the translation of undesirable protein.

Antisense and RNAi therapeutics market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Antisense and RNAi Therapeutics Market

Global Antisense and RNAi Therapeutics Market Scope and Market Size

Antisense and RNAi therapeutics market is segmented on the basis of indication, technology, and route of administration, end-users and distribution channel.

  • On the basis of indication, the antisense and RNAi therapeutics market is segmented into oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases and others.
  • The technology segment for antisense and RNAi therapeutics market includes RNA Interference, Antisense RNA. The RNA interference segment is further categorized into small interfering RNA (siRNA) and microRNAs (miRNAs).
  • Route of administration segment of antisense and RNAi therapeutics market is segmented into pulmonary delivery, intravenous injections, intra-dermal, intraperitoneal, topical and others.
  • On the basis of end-user, the antisense and RNAi therapeutics market is segmented into hospitals, specialty clinics and others.
  • Antisense and RNAi therapeutics market has also been segmented based on the distribution channel into hospital pharmacy, retail pharmacy others.

Antisense and RNAi Therapeutics Market Country Level Analysis

Global antisense and RNAi therapeutics market is analyzed and market size information is provided by country, indication, technology, and route of administration, end-users and distribution channel. as referenced above.

The countries covered in the antisense and RNAi therapeutics market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America is expected to account for the largest market share over coming years for the antisense and RNAi therapeutics market due to increase in rate of genetic disorders and number of FDA approval drugs. Europe is anticipated to have bright growth prospects in the coming years with escalating number of cases of chronic diseases while Asia-Pacific is expected to hold substantial growth due to the focus of various established market players to expand their presence in this particular region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Antisense and RNAi therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Antisense and RNAi Therapeutics Market Share Analysis

Antisense and RNAi therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to antisense and RNAi therapeutics market.

The major players covered in the antisense and RNAi therapeutics markets are Astellas Pharma Inc, Quark, Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma, Sanofi, Ionis Pharmaceuticals, Silence Therapeutics, Cenix BioScience, Sirnaomics, CureVac AG, BioNTech SE, Arrowhead Pharmaceuticals, Inc, Arbutus Biopharma, Marina Biotech, Inc and among others.

Key Market Development:

In August 2018, Alnylam Pharmaceuticals, Inc received an approval from the FDA for Onpattro (patisiran) contains a transthyretin-directed small interfering RNA for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The approval of Onpattro, RNA based therapy offers patients an innovative treatment for their symptoms that targets the underlying basis of this disease.

Customization Available : Global Antisense and RNAi Therapeutics Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19